GH Research Q3 2026 net loss narrows 11% to $12.45 million

PUBT · 1d ago
GH Research Q3 2026 net loss narrows 11% to $12.45 million
  • GH Research’s third-quarter 2026 net loss narrowed 11% year over year to $12.45 million.
  • Cash, cash equivalents and marketable securities rose 25% from December 31, 2025, to $350.6 million at September 30, 2026.
  • The treatment-resistant depression pivotal program is expected to begin shortly after a Q1 2027 FDA meeting, subject to final alignment.
  • A postpartum depression pivotal program is targeted to start in the second half of 2027, subject to final regulatory alignment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130800PRIMZONEFULLFEED9877166) on November 13, 2026, and is solely responsible for the information contained therein.